Deciphex raises €31m

“Act Venture Capital has been an unwavering partner throughout the journey, from our early vision to this new funding milestone. We chose Act for their reputation as a long-term, multi-stage investor who truly understands the challenges and opportunities of scaling ambitious ventures. Over the years, their team, led by John, has provided more than just capital; they’ve offered strategic insights, operational support, and a genuine commitment to our success.

Their ability to match our ambition and bring in value-added investors like Molten is a testament to their belief in our mission to revolutionize pathology with AI. We are proud to have Act as our partner and look forward to continuing this transformative journey together.”

Donal O’Shea

Five years ago, Donal presented a vision: using AI to transform pathology. The problem was clear – pathology underpins 90% of diagnoses and drug development, yet faces a critical global shortage of practitioners amid rising complexity.

This €31M funding announcement validates that vision. In just 5 years, Deciphex has achieved remarkable milestones:

€65M total raised

150+ employees

Top 10 pharma and CRO customers

1M+ pathology slides processed

At ACT, we’ve backed every funding round, with our largest check yet in this Series C. This reflects our commitment to supporting transformative founders from seed stage through major growth phases. While Deciphex is unique, their journey exemplifies our investment philosophy: identifying ambitious vision early and providing sustained support to realize that.

We welcome Molten to the journey and look forward to working closely together to support the Deciphex team.